



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

November 28, 2022

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code- 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- Biocon
--	--

Subject: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 ('SEBI Listing Regulation').

Dear Sir/Madam

In Compliance with Regulation 23(9) of SEBI Listing Regulations, please find enclosed disclosure of related party transactions on consolidated basis for the half year ended September 30, 2022, drawn in accordance with applicable accounting standard.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take on record the above information and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776

in INR Millions

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.

S. No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	In case monies are due to either party as a result of the transaction	In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)		
		PAN	Name				PAN	Relationship of the counterparty with the listed entity or its subsidiary	Opening balance	Closing balance		Nature /tenure/ advance/ inter-corporate deposit/ investment	Interest Rate (%)
1	Bicorn Limited												
2	Bicorn Limited												
3	Bicorn Limited												
4	Bicorn Limited												
5	Bicorn Limited												
6	Bicorn Limited												
7	Bicorn Limited												
8	Bicorn Limited												
9	Bicorn Limited												
10	Bicorn Limited												
11	Bicorn Limited												
12	Bicorn Limited												
13	Bicorn Limited												
14	Syngene International Limited												
15	Bicorn Biologics Limited												
16	Bicorn Biologics Limited												
17	Bicorn Biologics Limited												
18	Bicorn Biologics UK Limited												
19	Bicorn Biologics UK Limited												
20	Syngene International Limited												
21	Syngene International Limited												
22	Bicorn Therapeutics Inc.												
23	Bicorn FZ LLC												
24	Bicorn FZ LLC												
25	Bicorn FZ LLC												
26	Bicorn FZ LLC												
27	Bicorn Limited												
28	Bicorn Limited												
29	Syngene International Limited												
30	Bicorn Therapeutics LLC												
31	Bicorn Therapeutics Limited												
32	Bicorn Therapeutics LLC												
33	Bicorn Therapeutics Inc.												
34	Bicorn Therapeutics Inc.												
35	Bicorn Therapeutics Inc.												
36	Bicorn Therapeutics Inc.												
37	Bicorn Biologics Limited												
38	Bicorn Biologics Limited												
39	Syngene International Limited												
40	Syngene International Limited												
41	Bicorn Biologics Limited												
42	Syngene International Limited												
43	Syngene International Limited												
44	Bicorn Biologics Limited												
45	Bicorn Biologics Limited												
46	Bicorn Limited												
47	Syngene International Limited												
48	Bicorn Biologics Limited												
49	Bicorn Biologics Limited												
50	Bicorn Biologics Limited												

Notes:
 1. Share-based compensation expense allocable to key management personnel is Rs.37 which is not included in the remuneration disclosed above.
 2. The remuneration to key managerial personnel does not include the provisions made for gratuity and compensated absences, as they are obtained on an accrual basis for the Company as a whole.
 3. The above does not include allowance for expected credit loss amounting to Rs. 522 towards receivable from associate company.

